太原不排便的原因太原拉血,山西痔疮该挂什么科室,太原肛门坠胀痛,太原解大便很干怎么办,太原大便出血燥热,太原肛门溃烂是怎么回事,太原痔疮是啥

The United Nations Security Council unanimously adopted a US-drafted resolution to impose new sanctions on North Korea on Monday --- a move that comes just one week after the rogue nation carried out its sixth and largest nuclear test.The resolution is designed to accomplish six major goals: cap North Korea's oil imports, ban textile exports, end additional overseas laborer contracts, suppress smuggling efforts, stop joint ventures with other nations and sanction designated North Korean government entities, according to a US official familiar with negotiations.On Monday, the US?circulated a draft resolution that called for a full ban on exports of oil to North Korea and an asset freeze?on leader Kim Jong Un, the Worker's Party and the government of North Korea.But later in the day, the US put forward another draft that removed the full oil embargo, asset freeze, travel ban for Kim and softened the language on foreign workers and other issues. 974

The U.S. Geological Survey recorded two earthquakes in Tennessee early Wednesday.The first happened at about 3:15a.m. and was reported to be a magnitude 4.4. The second was recorded at about 3:30a.m. and was a magnitude 3.3.According to the USGS Intensity map, as of 3:45a.m., more than 2000 people reported feeling the earthquakes across Tennessee, North Carolina, Alabama, and Georgia.Some people reported feeling weak shaking in areas of Middle Tennessee, like Hendersonville, Cookeville, and Murfreesboro. According to the National Weather Service office in Morristown, the largest earthquake on record in East Tennessee was a magnitude 4.7 near Marysville in 1973. The USGS?studied the reason why earthquakes are felt at much farther distances on the east coast, compared with earthquakes that hit the west coast. Researchers found that some factors have to do with tectonic plates and their geological history. The east coast has older rocks, which researchers said allow seismic waves "to cross them more effectively during an earthquake." 1084

The suspect in the deadly terror attack in New York wasn't only a driver for Uber. He also worked for its rival Lyft.Lyft said late Wednesday that Sayfullo Saipov drove for its ride-hailing app in the past but that it deactivated his account as soon as he was identified as a suspect in the attack.Saipov, a 29-year-old from Uzbekistan who was living in New Jersey, has been charged with federal terrorism offenses in connection with Tuesday's attack in Manhattan in which eight people were killed.Uber said Tuesday that Saipov started driving for it in New Jersey just over six months ago, making more than 1,400 trips. It also banned him from its platform after the attack.Lyft didn't provide details on how long Saipov drove for its app or how many trips he made. It's not unusual for drivers to work for both companies.Saipov's case is drawing renewed attention to the background checks that ride-hailing companies carry out on their drivers.Records show Saipov received multiple traffic citations in the past, including failure to equip a motor vehicle carrier with or maintain a required brake system.Both Uber and Lyft said they hadn't come across any complaints about Saipov's safety as a driver for them.New Jersey rules for ride-hailing services like Uber and Lyft require the companies to conduct criminal background checks, which are usually outsourced to specialist firms. Convictions for crimes like reckless driving automatically disqualify a driver.Uber applies different criteria for background checks depending on state regulations. In general, drivers cannot have more than three minor moving violations, such as speeding tickets, in the past three years.Lyft's website says potential drivers are screened for "driving incidents" but doesn't specify what would disqualify them.Both Uber and Lyft say they are in contact with law enforcement authorities over the New York attack."Our thoughts are with those affected by this tragic act," Lyft said. 1999

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The US surgeon general issued an advisory Thursday recommending that more Americans carry the opioid overdose-reversing drug, naloxone.The drug, commonly known as Narcan, can very quickly restore normal breathing in someone suspected of overdosing on opioids, including heroin and prescription pain medications.Dr. Jerome Adams emphasized that "knowing how to use naloxone and keeping it within reach can save a life." To make his point, Adams relied on a rarely used tool: the surgeon general's advisory. The last such advisory was issued more than a decade ago and focused on drinking during pregnancy.Adams noted that the number of overdose deaths from prescription and illicit opioids doubled in recent years: from 21,089 deaths across the nation in 2010 to 42,249 in 2016.America's top doctor attributed this "steep increase" to several contributing factors, including "the rapid proliferation of illicitly made fentanyl and other highly potent synthetic opioids" and "an increasing number of individuals receiving higher doses of prescription opioids for long-term management of chronic pain.""Research shows that when naloxone and overdose education are available to community members, overdose deaths decrease in those communities," Adams said. Naloxone is used by police officers, first responders and emergency medical techs to reverse opioid overdoses. Adams added that increasing both the availability of naloxone and effective treatment is critical to ending the opioid epidemic.Speaking at the National Prescription Drug Abuse & Heroin Summit in Atlanta on Thursday morning, Adams addressed the potential "moral conflict" felt by some people who believe that providing naloxone "doesn't make a difference," since many people with drug addictions will just "go on and misuse substances again.""Well, that would be like me saying 'I'm not gonna go do surgery on this trauma patient because they're just gonna go out and speed again,' " he said.Adams noted that in most states, people who are or who know someone at risk for opioid overdose can get trained to use naloxone properly and also may receive naloxone by "standing order" -- without a prescription -- from pharmacies or some community-based programs."No mother should have to bury their child ,and especially not when there's a life-saving medication that virtually anyone can access," Adams said. "It is for this reason that I am issuing the first Surgeon General's Advisory in 13 years."The-CNN-Wire 2484